Roche’s HPV Test Approved As First-Line Cervical Cancer Screen
This article was originally published in The Gray Sheet
Executive Summary
The firm’s cobas human papillomavirus test is the first to gain approved labeling as a primary screen. It could be a market advantage for Roche, but the company now needs to work with clinical guideline developers to put the approved indication into routine practice.
You may also be interested in...
Big Week For HPV Dx: FDA Finalizes Guidance, Task Force Supports Solo Testing
An important task force drafted new recommendations supporting human papillomavirus tests as a solo first-line screen for cervical cancer in some women, followed up by a US FDA final guidance document detailing for test-makers how to best ensure assays for the cervical cancer-causing virus are safe and accurate.
Policy Briefs: What's New From FDA And CMS
Updates include an FDA safety communication for the Lariat suture device addressing use for left atrial appendage closure, new FDA draft guidance documents, and CMS proposals to cut radiation therapy payments and launch new payment models for hip and knee replacements.
CMS To Expand Screening Coverage For HIV, HPV
CMS took steps to expand coverage for two infectious diseases: a final decision memo to cover screening for human immunodeficiency virus irrespective of risk and a proposal to cover human papillomavirus screens in combination with Pap smears for women aged 30 to 65.